Cancer Research Grants  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 9637, October 15, 2007. doi: 10.1158/0008-5472.CAN-07-1489
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kokuryo, T.
Right arrow Articles by Hamaguchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kokuryo, T.
Right arrow Articles by Hamaguchi, M.

Priority Reports

Nek2 as an Effective Target for Inhibition of Tumorigenic Growth and Peritoneal Dissemination of Cholangiocarcinoma

Toshio Kokuryo1,2, Takeshi Senga2, Yukihiro Yokoyama1, Masato Nagino1, Yuji Nimura1 and Michinari Hamaguchi2

Divisions of 1 Surgical Oncology and 2 Cancer Biology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan

Requests for reprints: Michinari Hamaguchi, Division of Cancer Biology, Nagoya University Graduate School of Medicine, 65-Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Phone: 81-52-744-2462; Fax: 81-52-744-2464; E-mail: mhamagu{at}med.nagoya-u.ac.jp.

We investigated the role of Nek2, a member of the serine/threonine kinase family, Nek, in the tumorigenic growth of cholangiocarcinoma cells. Expression of Nek2 is elevated in cholangiocarcinoma in a tumor-specific manner as compared with that of normal fibroblast cells. Expression of exogenous Nek2 did not perturb the growth of cholangiocarcinoma cells, whereas suppression of the Nek2 expression with siRNA resulted in the inhibition of cell proliferation and induced cell death. In xenograft-nude mouse model, s.c. injection of Nek2 siRNA around the tumor nodules resulted in reduction of tumor size as compared with those of control siRNA injection. In peritoneal dissemination model, Nek2 siRNA–treated mice showed statistically longer survival periods in comparison with those of the control siRNA–treated mice. Taken together, our data indicate a pivotal role of Nek2 in tumorigenic growth of cholangiocarcinoma. [Cancer Res 2007;67(20):9637–42]




This article has been cited by other articles:


Home page
J. Cell Sci.Home page
J. Chang, R. H. Baloh, and J. Milbrandt
The NIMA-family kinase Nek3 regulates microtubule acetylation in neurons
J. Cell Sci., July 1, 2009; 122(13): 2274 - 2282.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.